NCT04027309
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04027309 |
| Title | A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML) |
| Acronym | HOVON 156 AML |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | Stichting Hemato-Oncologie voor Volwassenen Nederland |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | SWE | NOR | NLD | LTU | IRL | FRA | FIN | ESP | DEU | CHE | BEL | AUT | AUS |
CKB BOOST